Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin subcutaneous versus intravenous pharmacokinetic crossover study
2019-004884-32Phase 3Completed
- Sponsor
- CHU Caen Normandie
- Start
- Feb 2020
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of daptomycin (2 arms), sponsored by CHU Caen Normandie. Primary endpoint: Area under the concentration-time curve of daptomycin. Started Feb 2020; status: completed.
02
Drugs
daptomycin
Beyond the preview
Go deeper on 2019-004884-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004884-32.